Coya Therapeutics FY23 EPS $(0.79) Vs $(4.73) YoY; Collaboration Revenue Of 6M
Coya Therapeutics FY23 EPS $(0.79) Vs $(4.73) YoY; Collaboration Revenue Of 6M
Financial Results
财务业绩
As of December 31, 2023, Coya had cash and cash equivalents of $32.6 million and received an additional $7.5 million in January from Dr. Reddy's as an upfront payment as part of the COYA 302 licensing arrangement.
截至2023年12月31日，作为COYA 302许可安排的一部分，Coya拥有3,260万美元的现金及现金等价物，并于1月份从雷迪博士那里额外获得了750万澳元的预付款。
Research and development (R&D) expenses were $5.5 million for the year ended December 31, 2023, compared to $4.4 million for the year ended December 31, 2022. The change was primarily due to a $2.2 million increase in our preclinical expenses and a $0.5 million increase in internal research and development expenses, partially offset by a $1.4 million decrease in costs attributable to our sponsored research agreement with Houston Methodist Hospital and a $0.3 million decrease in costs for our clinical product candidate.
截至2023年12月31日的财年，研发（R&D）支出为550万美元，而截至2022年12月31日的年度为440万美元。这一变化主要是由于我们的临床前支出增加了220万美元，内部研发费用增加了50万美元，但部分被140万美元的成本减少所抵消，这归因于我们与休斯敦卫理公会医院的赞助研究协议，以及我们的临床候选产品成本减少了30万美元。
General and administrative expenses were $7.8 million for the year ended December 31, 2023, and $4.8 million for the year ended December 31, 2022, a change of approximately $3.0 million. The increase was primarily due to an increase in personnel related expenses arising from increases in employee headcount and an increase in our professional fees and consulting fees as we expanded our operations to support our research and development efforts.
截至2023年12月31日止年度的一般和管理费用为780万美元，截至2022年12月31日止年度的一般和管理费用为480万美元，变动约300万美元。增长的主要原因是员工人数增加导致的人事相关费用增加，以及随着我们扩大业务以支持研发工作，我们的专业费用和咨询费也有所增加。
Net loss was $8.0 million for the year ended December 31, 2023, compared to net loss of $12.2 million for the year ended December 31, 2022.
截至2023年12月31日止年度的净亏损为800万美元，而截至2022年12月31日止年度的净亏损为1,220万美元。
译文内容由第三方软件翻译。